DexCom, Inc. (NASDAQ:DXCM – Free Report) – Stock analysts at Leerink Partnrs issued their FY2028 EPS estimates for DexCom in a research report issued on Thursday, March 28th. Leerink Partnrs analyst M. Kratky anticipates that the medical device company will post earnings of $3.97 per share for the year. The consensus estimate for DexCom’s current full-year earnings is $1.76 per share.
DexCom (NASDAQ:DXCM – Get Free Report) last issued its earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The company’s revenue was up 26.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.34 earnings per share.
Get Our Latest Analysis on DexCom
DexCom Stock Performance
Shares of DXCM stock opened at $138.70 on Friday. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a fifty day moving average price of $125.54 and a 200 day moving average price of $112.03. The company has a market cap of $53.47 billion, a P/E ratio of 105.88, a PEG ratio of 2.40 and a beta of 1.18. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00.
Insider Buying and Selling
In related news, EVP Sadie Stern sold 4,137 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now directly owns 76,304 shares of the company’s stock, valued at $10,682,560. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Sadie Stern sold 4,137 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now directly owns 76,304 shares of the company’s stock, valued at $10,682,560. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 37,325 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $4,614,489.75. Following the transaction, the chief executive officer now directly owns 362,841 shares of the company’s stock, valued at $44,858,032.83. The disclosure for this sale can be found here. Insiders sold 183,635 shares of company stock valued at $24,020,621 over the last ninety days. Corporate insiders own 0.41% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KB Financial Partners LLC acquired a new position in DexCom during the first quarter worth about $72,000. Bartlett & CO. Wealth Management LLC acquired a new position in DexCom during the fourth quarter worth about $27,000. DSM Capital Partners LLC acquired a new position in DexCom during the fourth quarter worth about $28,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the period. Finally, MV Capital Management Inc. grew its position in DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Read More
- Five stocks we like better than DexCom
- Stock Average Calculator
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- The 3 Best Retail Stocks to Shop for in August
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.